Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
AstraZeneca and Daiichi's first co ... The companies are also seeking approval for the drug in patients with a type of lung cancer with a mutated form of a gene called EGFR, who have previously ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
The AstraZeneca/Daiichi Sankyo drug was evaluated in an open-label ... approval of the ADC for EGFR-mutated non-small cell lung cancer. A regulatory decision in this indication is expected in ...
AstraZeneca has received two separate recommendations ... which tested the combination of its lung cancer drugs Lazcluze (lazertinib) and Rybrevant (amivantamab-vmjw). J&J claims the combination ...